- Home
- LRE vs PRPO Comparison
LRE vs PRPO Comparison
Compare LRE & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- PRPO
- Stock Information
- Founded
- LRE 2001
- PRPO N/A
- Country
- LRE Japan
- PRPO United States
- Employees
- LRE N/A
- PRPO N/A
- Industry
- LRE
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- LRE
- PRPO Industrials
- Exchange
- LRE Nasdaq
- PRPO Nasdaq
- Market Cap
- LRE 20.5M
- PRPO 22.0M
- IPO Year
- LRE 2023
- PRPO N/A
- Fundamental
- Price
- LRE $2.22
- PRPO $17.55
- Analyst Decision
- LRE
- PRPO
- Analyst Count
- LRE 0
- PRPO 0
- Target Price
- LRE N/A
- PRPO N/A
- AVG Volume (30 Days)
- LRE 2.2M
- PRPO 16.8K
- Earning Date
- LRE 07-30-2015
- PRPO 11-05-2025
- Dividend Yield
- LRE N/A
- PRPO N/A
- EPS Growth
- LRE N/A
- PRPO N/A
- EPS
- LRE N/A
- PRPO N/A
- Revenue
- LRE $110,330,328.00
- PRPO $21,242,000.00
- Revenue This Year
- LRE N/A
- PRPO N/A
- Revenue Next Year
- LRE N/A
- PRPO N/A
- P/E Ratio
- LRE N/A
- PRPO N/A
- Revenue Growth
- LRE 3.92
- PRPO 27.05
- 52 Week Low
- LRE $1.00
- PRPO $3.90
- 52 Week High
- LRE $2.97
- PRPO $22.38
- Technical
- Relative Strength Index (RSI)
- LRE 73.39
- PRPO 53.87
- Support Level
- LRE $1.29
- PRPO $19.40
- Resistance Level
- LRE $2.97
- PRPO $22.38
- Average True Range (ATR)
- LRE 0.26
- PRPO 1.39
- MACD
- LRE 0.10
- PRPO -0.01
- Stochastic Oscillator
- LRE 61.93
- PRPO 40.33
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.